Tau PET has been acknowledged as the modality capable of detecting and assessing the topographical pattern of AD-specific tau pathology in vivo, although plasma biomarkers, such as MTBR-tau243, have been developed to detect AD tau proteinopathy2. Here, MAPT is linked to Alzheimer disease.